Nearly 90% of patients who received the combination therapy were still alive after 12 months compared with about 78% of patients who were alive after a year when treated with the older drug Sutent, data showed.
from Hindustan Times - lifestyle http://bit.ly/2DNIOYA
Post Top Ad
Saturday, 16 February 2019
Merck, Pfizer drug combo extends kidney cancer survival
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment